Nanoparticles loaded with STING agonists activate the cGAS-STING signalling pathway within the TME, resulting in IFN-β production and the activation of antigen-presenting cells, thereby stimulating the activation of tumour-reactive cytotoxic T cells (Covarrubias et al., 2022). This evidence concerns the gene STING1 and neoplasm.